Skip to content

Efficacy of Oxymetazoline on Clinical Symptoms and Cilia Function Following Radiofrequency Turbinate Reduction: A randomized controlled trial

Efficacy of Oxymetazoline on Clinical Symptoms and Cilia Function Following Radiofrequency Turbinate Reduction: A randomized controlled trial

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230321012
Enrollment
52
Registered
2023-03-21
Start date
2023-04-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients who undergo radiofrequency turbinate reduction for the treatment of inferior turbinate hypertrophy. Inferior turbinate hypertrophy Radiofrequency turbinate reduction Postoperative care Nasal obstruction

Interventions

The patient will receive the oxymetazoline nasal spray 2 puff per nostril every 8 hours for 2 weeks after surgery. ,The patient will receive the NSS nasal spray 2 puff per nostril every 8 hours for 2
Active Comparator Drug,Placebo Comparator Drug
Oxymetazoline nasal spray ,Normal saline nasal spray

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patients 18-year-old or older with chronic rhinitis either allergic rhinitis or non-allergic rhinitis who have failed at least 12-week medication therapy to control nasal obstructive symptom and have standard indication to go on radiofrequency for the turbinate reduction procedure.

Exclusion criteria

Exclusion criteria: The exclusion criteria include previous turbinate surgery, severe septal deviation and significant septal spur which the septoplasty is considered the concurrent treatment, evidence of rhinosinusitis on clinical history or endoscopy or radiology, nasal valve disorder and autoimmune, infectious or neoplasms diseases such as Wegener disease, cystic fibrosis and lymphoma. The patients who had contraindication for topical decongestant use included cardiovascular diseases, glaucoma, hyperthyroidism, BPH and patients who had depression and were taking an MAOI antidepressant or patients who had history of previous rebound rhinitis.

Design outcomes

Primary

MeasureTime frame
NOSE score At 1, 2 and 4 weeks NOSE score

Secondary

MeasureTime frame
VAS score of nasal obstruction At 0, 1, 2 and 4 weeks VAS score of nasal obstruction,Crusting score At 0, 1, 2 and 4 weeks Crusting score ,IT size At 0, 1, 2 and 4 weeks 4-point ordinal scale,Adverse effects (headache, palpitation, burning and dryness in the nose and mouth, rebound rhinitis ) At 0, 1, 2 and 4 weeks Categorical outcomes,Saccharin transportation time At 0 and 4 weeks Continuous outcome

Countries

Thailand

Contacts

Public ContactKangsadarn Tanjararak

Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand

kang006611@gmail.com0839166638

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026